Voglibot-GM 2.02

Description

Voglibose 0.2 mg + Glimepiride 2 mg + Metformin Hydrochloride 500 mg Tablet is an advanced triple-combination anti-diabetic formulation indicated for the management of Type 2 Diabetes Mellitus in adults when diet, exercise, and dual-drug therapy do not provide adequate glycemic control.

The three active ingredients work through complementary mechanisms to provide comprehensive blood glucose management:

Voglibose 0.2 mg delays the digestion and absorption of carbohydrates, helping reduce post-meal blood glucose spikes.
Glimepiride 2 mg stimulates insulin release from the pancreas to lower blood glucose levels.
Metformin Hydrochloride 500 mg reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity.

Manufactured in WHO-GMP certified facilities, this formulation ensures superior quality, safety, and efficacy, making it a high-demand product in the diabetology segment and an excellent addition to any pharma franchise portfolio.

Key Benefits

✔ Triple-action blood glucose control
✔ Helps reduce postprandial (post-meal) blood sugar levels
✔ Improves insulin sensitivity and glucose utilization
✔ Supports long-term management of Type 2 Diabetes Mellitus
✔ Complements diet and exercise for optimal glycemic control
✔ WHO-GMP certified quality manufacturing
✔ High demand anti-diabetic product for pharma franchise

Composition

Voglibose IP – 0.2 mg
Glimepiride IP – 2 mg
Metformin Hydrochloride IP – 500 mg

(Available in Immediate Release or Sustained Release variants as per market requirements.)

Indications / Uses

Type 2 Diabetes Mellitus
Inadequate glycemic control with dual therapy
Postprandial hyperglycemia
Long-term diabetes management under physician supervision

Dosage Form

Tablets

(Dosage should be taken strictly as directed by the physician.)

Packaging

Alu-Alu Blister Packaging
Strip Packaging
Premium anti-diabetic packaging
Custom private labeling available

Pharma Franchise Opportunity

We offer Voglibose + Glimepiride + Metformin Tablet Pharma Franchise with:

✅ Monopoly franchise rights
✅ WHO-GMP certified manufacturing
✅ High demand diabetic care product
✅ Promotional and marketing support
✅ Competitive pricing with attractive profit margins

This product is an excellent addition to diabetology, endocrinology, and chronic care pharma franchise portfolios, ensuring consistent prescription demand and long-term business growth.